Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Mazdutide with Metformin, Warfarin, Atorvastatin, and Digoxin in Overweight/Obese Subjects
NCT05815680Phase 1Completed
- Sponsor
- Innovent Biologics
- Start
- Apr 2023
- Primary completion
- Aug 2023
- Modality
- Hormonal Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of mazdutide in obesity and Overweight (2 arms), sponsored by Innovent Biologics. Primary endpoints: Maximum observed metformin plasma concentration at steady state up to 116 days, Area under the metformin plasma concentration-time curve up to 116 days and 6 more. Started Apr 2023; status: completed.
02
Drugs
mazdutide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT05815680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05815680.